Trial Profile
A Phase I Study of Once-Daily Oral DFP-11207 in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jun 2019
Price :
$35
*
At a glance
- Drugs DFP 11207 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Delta-Fly Pharma
- 04 Jun 2019 Pharmacokinetic and safety results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 25 Jan 2019 Status changed from recruiting to completed.
- 08 Dec 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2018.